AUTHORS
Nancy Asomaning, MS, CCRC, Rialnat A Lawal, MD, PhD2, Anna Conrey3, Swee Lay Thein, MD, DSc4
AFFILIATIONS
1 National Institutes of Health, Bethesda, Maryland, United States
2 National Institutes of Health, Bethesda, Maryland, United States
3 National Institutes of Health, Bethesda, Maryland, United States
4 National Institutes of Health, Bethesda, Maryland, United States
ABSTRACT
Hemoglobin SC (HbSC) is the second most common form of sickle cell disease (SCD), accounting for 25-30% of cases worldwide. Although generally considered a milder form of SCD, its clinical course can be highly variable. Genetic modifiers, including coinherited a-thalassemia, contribute to this variability. In people of Sub-Saharan African descent, α-thalassemia is most commonly caused by the 3.7-kb α-deletion, which reduces intracellular a-globin chains, which are positively charged. Because b-globin compete for a-globin binding, with affinity following the order bA > bS > bC, reduced a-globin chain availability in α-thalassemia is expected to preferentially decrease HbC in HbSC disease (and HbS in HbAS / HbSS), as a potential phenotypic modifier. We conducted a retrospective cross-sectional study to assess the role of alpha thalassemia in NIH patients with the HbSC genotype.
Data from 139 HbSC subjects enrolled between 2001-2026 on IRB-approved protocols NCT00011648 and NCT00081523 were included. All subjects are at least 18 years old and provided informed consent. Participants were not transfused at the time of sample collection. Alpha-globin genotyping was performed using droplet digital polymerase chain reaction and hemoglobin fractions were obtained using HPLC electrophoresis. Kruskal-Wallis test was used for group comparisons. Continuous variables were summarized as median (range) and categorical variables were summarized as counts and percentages. Statistical analysis was performed using R (version 2026.07.1).
The average age of subjects was 42 years (range: 18-86), 77 (55%) were females, 135 (97%) Black/African American, and 25 (18%) on hydroxyurea (HU). Our dataset consisted of 95 subjects with available alpha-globin data: 6 (6.3%) -α/-α, 26 (27.3%)-α/αα, 61 (64.2%) αα/αα, and 2 (2.10%) ααα/αα. The 2 subjects with ααα/αα were excluded from the analysis because of the small sample size. Of these 93 subjects, the median (range) SC ratio was 1.040 (0.944–1.255), HbA2 was 3.7% (2.5-5.0), mean corpuscular volume (MCV(fL)) was 78.1(58.7–119.3), mean corpuscular hemoglobin (MCH(pg)) was 28.1(20.9–42.9), and ferritin (ng/mL) was 136 (7.0–2128.0). Although median HbS (%) for coinherited α-thalassemia (-α/-α and -α/αα) was lower compared to wild type (αα/αα), (47.3% n=32 vs 48.0% n=61, p=0.416), it was not significant. Coinherited α-thalassemia, had significantly lower MCV (73.90 vs 81.50), MCH (26.10 vs 29.75), platelet count (K/mcL, 206 vs 287), and absolute lymphocytes (K/mcL, 1.75 vs 2.58), but higher RBC count (4.23 vs 3.83). Only the associations with MCV and MCH remained significant after correction for multiple testing (p<0.001).
The S:C ratio decreased with decreasing a-globin copy number: median (range) 1.044 (0.949-1.255) for αα/αα; 1.035 (0.949-1.221) for -α/αα; 1.021 (0.944-1.043) for -α/-α. Although this trend was not statistically significant (Kruskal-Wallis P = 0.102), it was contrary to what we expected.
Stratifying by S:C ratio (≤1 vs >1), among the 16 (17%) subjects with SC ≤1, genotype distribution was 1 (6.2%) -α/-α, 7 (43.8%) -α/αα, and 8 (50.0%) αα/αα, with median (range) S:C ratio of 0.944, 0.983 (0.949-1), and 0.960 (0.948-1), respectively (p=0.241). Among the 77 participants (83%) with S:C >1, distribution was 5 (6.5%) -α/-α, 19 (24.7%) -α/αα, and 53 (68.8%) αα/αα, with median (range) S:C of 1.028 (1.009-1.043), 1.042 (1.009-1.221), 1.049 (1.011-1.255), respectively (p=0.0911). A greater proportion of patients with single deletion (43.7% vs 24.7%) and double deletion (7.7% vs 6.5%) genotypes had S:C ratio ≤1.
Overall, about 33% of this cohort carried a-thalassemia, consistent with the expected 20-35% reported in the literature. Our HbSC SCD cohort showed slightly more HbS than HbC (S:C ratio: 1.040), similar to prior literature. However, contrary to expectation, we did not observe a consistent increase in HbS% relative to the more positively charged HbC despite α-globin chain loss; instead, the S:C ratio trended downward with decreasing α-globin copy number. Notably, 17% of the participants had S:C ≤1, and about half of these had coinherited α -thalassemia. These findings suggest the relationship between α-globin availability and β-globin variant selection in HbSC disease may be more complex than predicted by charge-based affinity alone, warranting further mechanistic investigation.
DISCLOSURES
Nancy Asomaning, MS, CCRC: No relevant conflicts of interest to declare.